Quantum BioPharma Ltd. income statement QNTM

Annual Quarterly

It recorded a net loss of $23.6 million.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

FY 2022
Dec 31, 2022
FY 2021
Dec 31, 2021
FY 2020
Dec 31, 2020
Research and development
7
+9.2%
6
-19.2%
8
Selling, general and administrative
15
-5.4%
16
+58.3%
10
Operating income
-27
+18.7%
-34
-9.9%
-31
Net income
-24
+33.1%
-35
-11.0%
-32
Weighted average shares, basic
39
—
—
Weighted average shares, diluted
1
-98.3%
35
+190.1%
12
+70.7%
Other measures
Depreciation and amortization
5
+12.2%
4
+3.7%
4
EBITDA
-23
+22.9%
-30
-10.9%
-27
Interest coverage
-432.57x
-486.19x
-130.28x
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
QNTM (Nasdaq)
Fiscal year ends
December 31
Incorporated in
Ontario, Canada
Headquarters
Toronto
SEC filer status
Non-accelerated filer, Emerging growth company
SEC CIK
1771885
Former names
FSD Pharma Inc. (until Aug 15, 2024)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.